Background: The rationale for studying the combination of bevacizumab, irinotecan, and temozolomide (BIT) in neuroblastoma (NB) is based on the following: (i) vascular endothelial growth factor (VEGF) expression is associated with an aggressive phenotype, (ii) anti-VEGF antibody bevacizumab enhances irinotecan-mediated suppression of NB xenografts, (iii) bevacizumab safety has been established in pediatric phase I studies, and (iv) irinotecan + temozolomide (IT) is a standard salvage chemotherapy. Results: Thirty-three heavily pretreated patients (nine primary refractory; 24 relapsed) received one to eight cycles of BIT. Toxicities were expected and transient. Grade 4 toxicities were neutropenia (30%) and thrombocytopenia (24%). Grade 3 toxicities included hepatic transaminitis (15%), proteinuria (9%), and diarrhea (3%). Overall responses were as follows: three CR (all in prior IT-treated patients), 18 no response, and 12 progressive disease. Only one of 23 patients assessable for the early stopping rule regarding efficacy achieved PR/CR, so patient accrual was discontinued. Median progression-free survival and overall survival was 7.7 ± 1.7 and 31.5 ± 5.6 months, respectively; all patients continued anti-NB therapy post-BIT.
INTRODUCTION
Intensive chemotherapy, aggressive surgery, radiotherapy, and anti-GD2 immunotherapy have improved survival rates for patients with high-risk neuroblastoma (NB), the most common extracranial pediatric solid tumor. [1] [2] [3] Nevertheless, many patients develop progressive disease (PD) and their long-term prognosis is poor. 4 Until recently, the most commonly accepted salvage regimen used for patients with Pediatr Blood Cancer 2017; 64: e26448 c 2017 Wiley Periodicals, Inc. 1 of 6 wileyonlinelibrary.com/journal/pbc relapsed and refractory disease was the combination of cyclophosphamide and topotecan. 5 However, the Children's Oncology Group (COG), the only cooperative pediatric oncology group in the United States, introduced this combination as an upfront treatment for newly diagnosed patients, making it a less attractive option in the setting of relapsed/refractory disease for fear of chemoresistance. Currently, the most widely used second-line chemotherapy regimen for patients with refractory or relapsed NB is the combination of irinotecan + temozolomide (IT). 6, 7 Irinotecan, a camptothecin prodrug activated by carboxylesterases to the active topoisomerase I inhibitor SN-38, has undergone phase I and phase II testing in children with NB using various dosing schedules. 8, 9 Toxicities included diarrhea and relatively modest myelosuppression. In general, although prolonged stabilization of disease was often observed, major response rates were <5%. 10, 11 Five-day courses of irinotecan alone were shown to be effective palliative therapy for patients with resistant NB. 12 Temozolomide, a methylating agent that generates O 6 -methylguanine in DNA, has modest activity against NB with myelosuppression as the main toxicity. 13 Methylationof O 6 -guanine by temozolomide may lead to recruitment of topoisomerase I and potentially enhance the probability of inducing camptothecin-mediated damage. This possibility, and the lack of overlapping major toxicities, formed the biochemical rationale for combining temozolomide with irinotecan. 14 A phase I study established the toxicity profile (grade 1-2 diarrhea and myelosuppression) of the combination in heavily prior-treated pediatric patients. 15 Although multiple courses entailed no cumulative toxicity and controlled disease for prolongedperiods in many patients, reported objective response rates in patients with relapsed or refractory NB were generally <25%. 6, 7 Angiogenesis is a significant regulator of NB growth and tumor vascularity correlates with high-risk disease. 16, 17 The pro-angiogenic vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are considered to play a critical role in the initiation of tumor angiogenesis. 18 Expression of VEGF and VEGFR correlates with a higher stage of NB. 19, 20 Furthermore, VEGF may act as a growth factor for NB cells independent of its pro-angiogenic action. 21 Bevacizumab, a humanized monoclonal antibody 22 binding all five isoforms of human VEGF, has been extensively studied in adults with cancer and has US Food and Drug Administration (FDA) approval for the therapy of several cancers usually in combination with chemotherapy. 23 Like other antiangiogenic agents, its antitumor effect is attributed to normalization of tumor vasculature. The safety of bevacizumab was established in children with resistant solid tumors in a phase I trial conducted by the COG. Dose-limiting toxicity was not reached up to a dose of 15 mg/kg administered intravenously (IV) every 14 days, and the toxicity profile was similar to that seen in adults. 24 In anecdotal reports in pediatric patients with relapsed malignancies, significant adverse events appeared to be more frequent especially in children with brain tumors. 25, 26 Pharmacokinetic parameters in children were similar to those measured in adults 27 as were objective responses when used as a single agent.
In preclinical studies of NB xenografts, bevacizumab transiently normalized tumor vasculature 28 but only partially suppressed tumor growth. 29 Diminished VEGF gene and protein expression were associated with response of NB xenografts to irinotecan. 30 In experiments performed in our laboratory, we observed insignificant tumor suppres- 
METHODS

Patient selection
High-risk NB patients with a history of tumor progression or recurrence or failure to achieve complete response (CR) after induction chemotherapy were eligible. They were required to have measurable or evaluable disease and a minimum life expectancy of 8 weeks. 
Treatment and monitoring
Biostatistical considerations
Since best responses in NB patients treated with IT can occur beyond two cycles, the primary endpoint chosen was efficacy of BIT as assessed by response after four cycles. 6, 7 If patients had PD before completing four cycles, treatment was considered to have failed, and such patients were not replaced on study. Patients withdrawing from study prior to completing four cycles due to reasons other than PD, for example, BIT toxicity or parent/physician preferences, were replaced.
Based on reported historical responses to IT, we proposed declaring treatment effective if probability of response was ≥0. 
RESULTS
Patient characteristics
Thirty-three patients with a median age of 6.4 (range 2. 
Responses
Best overall responses by INRC in all 33 patients were 3 (9%) CR, 18 (55%) NR, and 12 (36%) PD (Table 2) . Sixteen patients were withdrawn before receiving four cycles: six had PD and were not replaced, two had unacceptable toxicities (one with prolonged myelosuppression and one with persistent proteinuria) and were replaced, and a further eight patients were withdrawn before four cycles due to parental request. Among the 23 patients evaluable for the defined efficacy endpoint (i.e., response to BIT after four cycles), responses were 1 (4%) CR, 13 (57%) NR, and 9 (27%) PD. Thirty-two patients had MIBG-avid skeletal disease at enrollment, with a median modified Curie score of 7 CR, complete response; INRC, International Neuroblastoma Response Criteria; NR, no response; PD, progressive disease; PR, partial response. a PR for MIBG scans was defined as >50% but <100% reduction in MIBG score while NR was <50% reduction but no increase in MIBG score. E l e v a t e dA S T 
TA B L E 2 Responses
TA B L E 3 Related toxicities
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Total (n = 33)
Toxicities
In general, BIT was well tolerated ( Table 3 ). The treatment was outpatient and all toxicities were expected based on prior reports of separately administered IT and bevacizumab. Toxicities were transient, resolving without any intervention apart from supportive care. Progression-Free Survival F I G U R E 1 Survival in neuroblastoma patients treated with bevacizumab, irinotecan, and temozolomide (BIT) grade 2 hypertension. All patients were followed for late toxicities:
no unexpected toxicities were observed; however, one patient who had received extensive prior treatment developed secondary acute myeloid leukemia 2.3 years after completing BIT.
Postprotocol therapy and survival
All patients went on to receive additional therapy after coming off study. Subsequent therapies included immunotherapy with the anti-GD2 monoclonal antibody 3F8 (n = 14). The contribution of BIT, if any, to prolonging survival could not be evaluated. Median progressionfree survival (PFS) and overall survival (OS) were 7.7 ± 1.7 months and 31.5 ± 5.6 months, respectively (Fig. 1) . Three-year PFS and OS probabilities were 10 ± 5% and 39 ± 9%, respectively. Seven patients are currently long-term (>3 years from BIT) survivors: four with residual disease, two in CR despite post-BIT relapses, and one in continuous remission. Survival did not correlate with response to BIT.
DISCUSSION
The combination of IT has been widely used as salvage therapy for chemorefractory or relapsed NB, especially after 2005 when topotecan was added to upfront therapy in COG protocols. 33 We previously reported our experience with a 5-day regimen of the combination for resistant high-risk NB and demonstrated that IT could be delivered as outpatient therapy with modest toxicity. Mild myelosuppressive effects allowed for use when BM reserve was limited. However, major responses (CR + PR by INRC, as used in this current study) were uncommon (<10%). We and others have attempted to enhance the anti-NB activity of irinotecan or IT by combining standard or newer chemotherapeutic 34 agents such as temsirolimus, 35 gefitinib, 36 or alisertib, 37 or targeted radiotherapy with 131 I-MIBG. 38 However, response rates were not significantly improved ranging from 0 to 25%. We hypothesized that adding an agent that provides inhibition of angiogenesis, an important oncogenic pathway that was not previously targeted in high-risk NB, would improve the CR + PR rates to a benchmark of 35%. Unfortunately, in our study the response rate to BIT, as assessed by INRC, was only 9%. Even if response criteria are modified to allow ≥50% reduction in Curie scores on MIBG scans to be deemed PR, the response rate was only 18% (six of 33 patients). This suboptimal response rate resulted in termination of the study after the first phase as mandated by the Simon two-stage design. All three patients who achieved CR and seven of nine patients with objective responses by MIBG scan had previously received, though had not progressed on, IT suggesting that prior IT therapy did not account for the low response rate. Based on our data and experience with the abovementioned combination studies, it is unlikely that adding anti-VEGF agents to the "backbone" of IT will improve response rates significantly beyond 25%.
In children, the combination of bevacizumab and irinotecan has primarily been studied in patients with brain tumors. Bevacizumab confers PFS benefit in adults with glioblastoma multiforme and received FDA approval for this indication. 39 However, in the pediatric population, the combination of bevacizumab and irinotecan was ineffective in recurrent malignant glioma and ependymoma. 40 For other pediatric tumors, there are only anecdotal reports on the use of BIT. Responses have been observed in patients with Ewing sarcoma 41 and Wilms tumor. 42 BIT toxicities encountered in our study were similar to those reported in adults with hypertension, fatigue, epistaxis, and proteinuria being the commonest. Compared to our study, a higher number of children receiving BIT for brain tumors (6% vs. 24%) stopped therapy due to toxicity. 43 Although there were no long-term adverse events in NB patients treated with BIT, the addition of bevacizumab did add several toxicities that interfered with patient quality of life.
The most common of these (39%) was epistaxis, which even though not severe required nasal pressure and infrequently, nasal packing. Severe side effects of bevacizumab such as severe hypertension and gastrointestinal perforation, albeit rarer than in adults, have been described in children necessitating vigilance while using bevacizumab in this population. 43 Ours is the first pediatric phase II study of bevacizumab either as a single agent or in combination with chemotherapy for any non-CNS tumor. As observed in brain tumor patients, <10% of our high-risk NB study patients had major responses. We did not evaluate possible mechanisms for this lack of efficacy. However, several mechanisms for treatment failure could be considered including dependence on VEGFindependent angiogenesis pathways, upregulation of pro-angiogenic, and other tumor stromal factors. Despite overall manageable toxicity, the results from this phase II study do not support the addition of bevacizumab to standard chemotherapy regimens for high-risk NB.
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